SELLAS Life Sciences (SLS) EBITDA (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly EBITDA of -$9.3 million for Q1 2026, down 52.6% year-over-year from -$19.5 million in Q1 2025, and down 12.08% quarter-over-quarter from -$8.3 million in Q4 2025.
SELLAS Life Sciences (SLS) EBITDA (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported EBITDA for 15 consecutive years, with -$9.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 52.6% year-over-year to -$9.3 million; the TTM figure through Mar 2026 stood at -$31.5 million (down 12.65% YoY), while the FY2025 annual figure was -$28.3 million, up 10.28% from the prior year.
- EBITDA retreated to -$9.3 million in Q1 2026 per SLS's latest filing, from -$8.3 million in the prior quarter.
- Across five years, EBITDA topped out at -$6.1 million in Q1 2025 and bottomed at -$16.7 million in Q1 2022.
- Historically, EBITDA has averaged -$8.8 million across 5 years, with a median of -$8.3 million in 2025.
- Annual changes were most pronounced in 2022 — EBITDA tumbled 645.43% — and 2025, when it surged 37.14%.
- SELLAS Life Sciences' EBITDA stood at -$9.4 million in 2022, then rose by 13.43% to -$8.2 million in 2023, then advanced by 15.4% to -$6.9 million in 2024, then slipped by 19.33% to -$8.3 million in 2025, then declined by 12.08% to -$9.3 million in 2026.
- Business Quant data shows SLS's EBITDA at -$9.3 million in Q1 2026, -$8.3 million in Q4 2025, and -$7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | -10.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.63 Mn |
| Mar 31, 2026 | -9.25 Mn |
| Dec 31, 2025 | -8.26 Mn |
| Sep 30, 2025 | -7.08 Mn |
| Jun 30, 2025 | -6.87 Mn |
| Mar 31, 2025 | -6.06 Mn |
| Dec 31, 2024 | -6.92 Mn |
| Sep 30, 2024 | -7.33 Mn |
| Jun 30, 2024 | -7.62 Mn |
| Mar 31, 2024 | -9.65 Mn |
| Dec 31, 2023 | -8.18 Mn |
| Sep 30, 2023 | -9.36 Mn |
| Jun 30, 2023 | -9.05 Mn |
| Mar 31, 2023 | -11.28 Mn |
| Dec 31, 2022 | -9.45 Mn |
| Sep 30, 2022 | -7.15 Mn |
| Jun 30, 2022 | -8.62 Mn |
| Mar 31, 2022 | -16.74 Mn |
| Dec 31, 2021 | -11.62 Mn |
| Sep 30, 2021 | -6.98 Mn |